Literature DB >> 21525424

Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.

M H Rosenbloom1, A Alkalay, N Agarwal, S L Baker, J P O'Neil, M Janabi, I V Yen, M Growdon, J Jang, C Madison, E C Mormino, H J Rosen, M L Gorno-Tempini, M W Weiner, B L Miller, W J Jagust, G D Rabinovici.   

Abstract

BACKGROUND/
OBJECTIVE: Patients with posterior cortical atrophy (PCA) often have Alzheimer disease (AD) at autopsy, yet are cognitively and anatomically distinct from patients with clinical AD. We sought to compare the distribution of β-amyloid and glucose metabolism in PCA and AD in vivo using Pittsburgh compound B (PiB) and FDG-PET.
METHODS: Patients with PCA (n = 12, age 57.5 ± 7.4, Mini-Mental State Examination [MMSE] 22.2 ± 5.1), AD (n = 14, age 58.8 ± 9.6, MMSE 23.8 ± 6.7), and cognitively normal controls (NC, n = 30, age 73.6 ± 6.4) underwent PiB and FDG-PET. Group differences in PiB distribution volume ratios (DVR, cerebellar reference) and FDG uptake (pons-averaged) were assessed on a voxel-wise basis and by comparing binding in regions of interest (ROIs).
RESULTS: Compared to NC, both patients with AD and patients with PCA showed diffuse PiB uptake throughout frontal, temporoparietal, and occipital cortex (p < 0.0001). There were no regional differences in PiB binding between PCA and AD even after correcting for atrophy. FDG patterns in PCA and AD were distinct: while both groups showed hypometabolism compared to NC in temporoparietal cortex and precuneus/posterior cingulate, patients with PCA further showed hypometabolism in inferior occipitotemporal cortex compared to both NC and patients with AD (p < 0.05). Patients with AD did not show areas of relative hypometabolism compared to PCA.
CONCLUSIONS: Fibrillar amyloid deposition in PCA is diffuse and similar to AD, while glucose hypometabolism extends more posteriorly into occipital cortex. Further studies are needed to determine the mechanisms of selective network degeneration in focal variants of AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525424      PMCID: PMC3100124          DOI: 10.1212/WNL.0b013e31821cccad

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

3.  Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.

Authors:  Randy L Buckner; Jorge Sepulcre; Tanveer Talukdar; Fenna M Krienen; Hesheng Liu; Trey Hedden; Jessica R Andrews-Hanna; Reisa A Sperling; Keith A Johnson
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

4.  Neurodegenerative diseases target large-scale human brain networks.

Authors:  William W Seeley; Richard K Crawford; Juan Zhou; Bruce L Miller; Michael D Greicius
Journal:  Neuron       Date:  2009-04-16       Impact factor: 17.173

5.  Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex.

Authors:  Taiki Kambe; Yumiko Motoi; Kenji Ishii; Nobutaka Hattori
Journal:  J Neurol       Date:  2010-03       Impact factor: 4.849

6.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

7.  Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation.

Authors:  Olli Tenovuo; Nina Kemppainen; Sargo Aalto; Kjell Någren; Juha O Rinne
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

8.  Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.

Authors:  R Migliaccio; F Agosta; K Rascovsky; A Karydas; S Bonasera; G D Rabinovici; B L Miller; M L Gorno-Tempini
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

9.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Authors:  Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust
Journal:  Brain       Date:  2010-01-15       Impact factor: 13.501

10.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.

Authors:  Marsel Mesulam; Alissa Wicklund; Nancy Johnson; Emily Rogalski; Gabriel C Léger; Alfred Rademaker; Sandra Weintraub; Eileen H Bigio
Journal:  Ann Neurol       Date:  2008-06       Impact factor: 10.422

View more
  58 in total

1.  Posterior cortical atrophy: evidence for discrete syndromes of early-onset Alzheimer's disease.

Authors:  Po-Heng Tsai; Edmond Teng; Collin Liu; Mario F Mendez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-08-09       Impact factor: 2.035

2.  Approach to atypical Alzheimer's disease and case studies of the major subtypes.

Authors:  Bradford C Dickerson; Scott M McGinnis; Chenjie Xia; Bruce H Price; Alireza Atri; Melissa E Murray; Mario F Mendez; David A Wolk
Journal:  CNS Spectr       Date:  2017-02-15       Impact factor: 3.790

3.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

4.  Biparietal variant of Alzheimer's disease: a rare presentation of a common disease.

Authors:  Inês B Marques; Miguel Tábuas-Pereira; Miguel Milheiro; Isabel Santana
Journal:  BMJ Case Rep       Date:  2015-01-05

Review 5.  Posterior Cortical Atrophy.

Authors:  Jonathan M Schott; Sebastian J Crutch
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 6.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 7.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

Review 8.  Dementia and neuroimaging.

Authors:  Federica Agosta; Francesca Caso; Massimo Filippi
Journal:  J Neurol       Date:  2012-12-15       Impact factor: 4.849

Review 9.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

Review 10.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.